Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents.
Antineoplastic Agents
/ chemical synthesis
Caspase 8
/ metabolism
Cell Line, Tumor
Cell Proliferation
/ drug effects
Dose-Response Relationship, Drug
Drug Design
Drug Screening Assays, Antitumor
Enzyme Inhibitors
/ chemical synthesis
Humans
Immunologic Factors
/ chemical synthesis
Molecular Structure
NF-kappa B
/ antagonists & inhibitors
Structure-Activity Relationship
Thalidomide
/ chemical synthesis
Tumor Necrosis Factor-alpha
/ antagonists & inhibitors
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Anticancer
Apoptosis
Immunomodulators
Thalidomide
Journal
Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
26
02
2020
revised:
04
06
2020
accepted:
22
08
2020
pubmed:
16
9
2020
medline:
30
3
2021
entrez:
15
9
2020
Statut:
ppublish
Résumé
Thalidomide and its analogs are immunomodulatory drugs that inhibit the production of certain inflammatory mediators associated with cancer. In the present work, a new series of thalidomide analogs was designed and synthesized to obtain new effective antitumor immunomodulatory agents. The synthesized compounds were evaluated for their cytotoxic activities against a panel of four cancer cell lines (HepG-2, HCT-116, PC3 and MCF-7). Compounds 33
Identifiants
pubmed: 32932121
pii: S0045-2068(20)31515-7
doi: 10.1016/j.bioorg.2020.104218
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Enzyme Inhibitors
0
Immunologic Factors
0
NF-kappa B
0
Tumor Necrosis Factor-alpha
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Thalidomide
4Z8R6ORS6L
CASP8 protein, human
EC 3.4.22.-
Caspase 8
EC 3.4.22.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104218Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.